Get the Stockscreener App
54.65
0.53%
-0.29
After Hours:
54.69
0.04
+0.07%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $54.65, with a volume of 9.70M.
It is down -0.53% in the last 24 hours and up +0.68% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$54.94
Open:
$54.98
24h Volume:
9.70M
Relative Volume:
0.65
Market Cap:
$111.25B
Revenue:
$48.03B
Net Income/Loss:
$6.05B
P/E Ratio:
18.45
EPS:
2.9615
Net Cash Flow:
$15.30B
1W Performance:
-1.10%
1M Performance:
+0.68%
6M Performance:
+11.58%
1Y Performance:
-7.59%
1-Day Range:
$54.23
$55.18
1-Week Range:
$53.55
$55.52
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
54.65 | 111.84B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,064.29 | 973.23B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
220.14 | 526.41B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.26 | 385.48B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.14 | 278.22B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.26 | 276.52B | 46.69B | 15.29B | 9.25B | 3.4329 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb Company $BMY Shares Sold by Quilter Plc - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
1 ETF Could Turn $500 Monthly Into a $800,000 Portfolio That Pays $24,000 in Annual Dividend Income - The Motley Fool
Bristol Myers Squibb: The Rerating Was FastThe Proof Will Be Slow (Rating Downgrade) - Seeking Alpha
Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments - Yahoo Finance UK
Bristol Myers Squibb and Janux Launch Partnership on Tumor-Activated T Cell Engagers - Oncodaily
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? - Finviz
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
BMS snags top neuro researcher from Eisai—Chutes & Ladders - Fierce Biotech
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Did AI Lung Imaging And New HCM Data Just Shift Bristol Myers Squibb’s (BMY) Investment Narrative? - simplywall.st
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com India
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
BMS bets on Janux’s novel solid tumour therapy through $850m deal - Pharmaceutical Technology
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors - marketscreener.com
Bristol Myers buys into Janux’s ‘masked’ T cell engagers - BioPharma Dive
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
Janux stock rises after Bristol Myers Squibb collaboration deal By Investing.com - Investing.com South Africa
Is BMY's Deep Pipeline the Key to Its Next Growth Phase? - Yahoo Finance
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
BMS pens $850M solid tumor pact with T-cell engager biotech Janux - Fierce Biotech
Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb - marketscreener.com
Janux, Bristol Myers Squibb partner on tumor-activated therapy - Investing.com
Janux Therapeutics stock soars after Bristol Myers Squibb collaboration - Investing.com
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer - marketscreener.com
Bristol Myers taps Janux cancer tech in deal worth up to $800M - Stock Titan
Hepatitis Therapeutics Market Overview and Leading Players: - openPR.com
Bristol Myers Squibb teams up with Microsoft for AI-powered lung cancer detection - Mugglehead Magazine
Bristol-Myers' Worker Arbitration Push Scrutinized On Appeal - Law360
Bristol-Myers (BMY): UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery - Insider Monkey
15 Best High Yield Stocks To Buy - Insider Monkey
Syngene Extends Research Collaboration with Bristol Myers Squibb till 2035 - Chemical Industry Digest
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences - Benzinga
Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026 - Finviz
Bristol Myers Squibb and Microsoft partner to detect lung cancer earlier By Investing.com - Investing.com South Africa
Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock - Insider Monkey
Bristol Myers (BMY) Teams Up with Microsoft for Lung Cancer Dete - GuruFocus
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - Yahoo Finance
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 - Yahoo Finance
Microsoft (MSFT) and Bristol Myers Squibb (BMY) Partner to Enhan - GuruFocus
Bristol Myers partners with Microsoft for AI-driven lung cancer detection - Reuters
Guggenheim Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $62 - 富途资讯
Bristol Myers partners with Microsoft for AI-driven lung cancer detection By Reuters - Investing.com
Bristol Myers Squibb Partners With Microsoft On AI Lung Cancer Detection - Nasdaq
Bristol Myers Squibb and Microsoft partner to detect lung cancer earlier - Investing.com
Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026 - Finviz
2 Top Blue-Chip Stocks to Buy and Hold in 2026 - Morningstar
Transparency & reporting - Bristol Myers Squibb
2 Dividend Stocks to Buy and Hold For 10 Years - Finviz
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):